Who makes OCR-002 IV Solution?

OCR-002 IV Solution is developed by Ocera Therapeutics, Inc..

What development phase is OCR-002 IV Solution in?

OCR-002 IV Solution is in Phase 1.

What are the side effects of OCR-002 IV Solution?

Common side effects include Hypophosphataemia, Anaemia, Hypokalaemia, Pyrexia, Urinary tract infection.

Last reviewed 2026-04-20 · How we verify

OCR-002 IV Solution

Ocera Therapeutics, Inc. · Phase 1 active Small molecule Quality 5/100

At a glance

Generic name	OCR-002 IV Solution
Also known as	Ornithine phenylacetate
Sponsor	Ocera Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Hypophosphataemia
Anaemia
Hypokalaemia
Pyrexia
Urinary tract infection

Key clinical trials

OCR002-SP103 - Oral Immediate Release Study (PHASE1)
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OCR-002 IV Solution CI brief — competitive landscape report
OCR-002 IV Solution updates RSS · CI watch RSS
Ocera Therapeutics, Inc. portfolio CI